Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

López Lacort, Mónica; Múñoz Quiles, Cintia; Mira Iglesias, Ainara; López Labrador, F. Xavier; Mengual Chuliá, Beatriz; Fernández García, Carlos; Carballido Fernández, Mario; Pineda Caplliure, Ana; Mollar Maseres, Juan; Benavent, Maruan Shalabi; Sanz Herrero, Francisco; Zornoza Moreno, Matilde; Pérez Martín, Jaime Jesús; Alfayate Miguelez, Santiago; Pérez Crespo, Rocío; Bastida Sánchez, Encarnación; Menasalvas Ruiz, Ana Isabel; Téllez González, Mª Cinta; Esquiva Soto, Samuel; Del Toro Saravia, Carlos; Sanz Muñoz, Iván; Eiros, José María; Matías Del Pozo, Vanesa; Toquero Asensi, Marina; Pastor Villalba, Eliseo; Lluch Rodrigo, José Antonio; Díez Domingo, Javier; Orrico Sánchez, Alejandro

Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage...

Descripción completa

Detalles Bibliográficos
Autores:	López Lacort, Mónica, Múñoz Quiles, Cintia, Mira Iglesias, Ainara, López Labrador, F. Xavier, Mengual Chuliá, Beatriz, Fernández García, Carlos, Carballido Fernández, Mario, Pineda Caplliure, Ana, Mollar Maseres, Juan, Benavent, Maruan Shalabi, Sanz Herrero, Francisco, Zornoza Moreno, Matilde, Pérez Martín, Jaime Jesús, Alfayate Miguelez, Santiago, Pérez Crespo, Rocío, Bastida Sánchez, Encarnación, Menasalvas Ruiz, Ana Isabel, Téllez González, Mª Cinta, Esquiva Soto, Samuel, Del Toro Saravia, Carlos, Sanz Muñoz, Iván, Eiros, José María, Matías Del Pozo, Vanesa, Toquero Asensi, Marina, Pastor Villalba, Eliseo, Lluch Rodrigo, José Antonio, Díez Domingo, Javier, Orrico Sánchez, Alejandro
Tipo de recurso:	artículo
Fecha de publicación:	2024
País:	España
Institución:	Universidad Católica de Valencia San Vicente Mártir
Repositorio:	RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:	inglés
OAI Identifier:	oai:riucv.ucv.es:20.500.12466/4335
Acceso en línea:	http://hdl.handle.net/20.500.12466/4335
Access Level:	acceso abierto
Palabra clave:	Nirsevimab immunoprophylaxis Hospital admission Respiratory syncytial virus lower Respiratory tract infections Infants 32 Ciencias Médicas

id	ES_e749dc133fcef7cc8e61dcfb55e4e441
oai_identifier_str	oai:riucv.ucv.es:20.500.12466/4335
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024López Lacort, MónicaMúñoz Quiles, CintiaMira Iglesias, AinaraLópez Labrador, F. XavierMengual Chuliá, BeatrizFernández García, CarlosCarballido Fernández, MarioPineda Caplliure, AnaMollar Maseres, JuanBenavent, Maruan ShalabiSanz Herrero, FranciscoZornoza Moreno, MatildePérez Martín, Jaime JesúsAlfayate Miguelez, SantiagoPérez Crespo, RocíoBastida Sánchez, EncarnaciónMenasalvas Ruiz, Ana IsabelTéllez González, Mª CintaEsquiva Soto, SamuelDel Toro Saravia, CarlosSanz Muñoz, IvánEiros, José MaríaMatías Del Pozo, VanesaToquero Asensi, MarinaPastor Villalba, EliseoLluch Rodrigo, José AntonioDíez Domingo, JavierOrrico Sánchez, AlejandroNirsevimab immunoprophylaxisHospital admissionRespiratory syncytial virus lowerRespiratory tract infectionsInfants32 Ciencias MédicasThe monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage range: 79–99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.20242024-06-0520242024-02-0820242024-02-08journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12466/4335reponame:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártirinstname:Universidad Católica de Valencia San Vicente MártirInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:riucv.ucv.es:20.500.12466/43352026-06-19T08:32:07Z
dc.title.none.fl_str_mv	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
title	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
spellingShingle	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024 López Lacort, Mónica Nirsevimab immunoprophylaxis Hospital admission Respiratory syncytial virus lower Respiratory tract infections Infants 32 Ciencias Médicas
title_short	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
title_full	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
title_fullStr	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
title_full_unstemmed	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
title_sort	Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
dc.creator.none.fl_str_mv	López Lacort, Mónica Múñoz Quiles, Cintia Mira Iglesias, Ainara López Labrador, F. Xavier Mengual Chuliá, Beatriz Fernández García, Carlos Carballido Fernández, Mario Pineda Caplliure, Ana Mollar Maseres, Juan Benavent, Maruan Shalabi Sanz Herrero, Francisco Zornoza Moreno, Matilde Pérez Martín, Jaime Jesús Alfayate Miguelez, Santiago Pérez Crespo, Rocío Bastida Sánchez, Encarnación Menasalvas Ruiz, Ana Isabel Téllez González, Mª Cinta Esquiva Soto, Samuel Del Toro Saravia, Carlos Sanz Muñoz, Iván Eiros, José María Matías Del Pozo, Vanesa Toquero Asensi, Marina Pastor Villalba, Eliseo Lluch Rodrigo, José Antonio Díez Domingo, Javier Orrico Sánchez, Alejandro
author	López Lacort, Mónica
author_facet	López Lacort, Mónica Múñoz Quiles, Cintia Mira Iglesias, Ainara López Labrador, F. Xavier Mengual Chuliá, Beatriz Fernández García, Carlos Carballido Fernández, Mario Pineda Caplliure, Ana Mollar Maseres, Juan Benavent, Maruan Shalabi Sanz Herrero, Francisco Zornoza Moreno, Matilde Pérez Martín, Jaime Jesús Alfayate Miguelez, Santiago Pérez Crespo, Rocío Bastida Sánchez, Encarnación Menasalvas Ruiz, Ana Isabel Téllez González, Mª Cinta Esquiva Soto, Samuel Del Toro Saravia, Carlos Sanz Muñoz, Iván Eiros, José María Matías Del Pozo, Vanesa Toquero Asensi, Marina Pastor Villalba, Eliseo Lluch Rodrigo, José Antonio Díez Domingo, Javier Orrico Sánchez, Alejandro
author_role	author
author2	Múñoz Quiles, Cintia Mira Iglesias, Ainara López Labrador, F. Xavier Mengual Chuliá, Beatriz Fernández García, Carlos Carballido Fernández, Mario Pineda Caplliure, Ana Mollar Maseres, Juan Benavent, Maruan Shalabi Sanz Herrero, Francisco Zornoza Moreno, Matilde Pérez Martín, Jaime Jesús Alfayate Miguelez, Santiago Pérez Crespo, Rocío Bastida Sánchez, Encarnación Menasalvas Ruiz, Ana Isabel Téllez González, Mª Cinta Esquiva Soto, Samuel Del Toro Saravia, Carlos Sanz Muñoz, Iván Eiros, José María Matías Del Pozo, Vanesa Toquero Asensi, Marina Pastor Villalba, Eliseo Lluch Rodrigo, José Antonio Díez Domingo, Javier Orrico Sánchez, Alejandro
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv	Nirsevimab immunoprophylaxis Hospital admission Respiratory syncytial virus lower Respiratory tract infections Infants 32 Ciencias Médicas
topic	Nirsevimab immunoprophylaxis Hospital admission Respiratory syncytial virus lower Respiratory tract infections Infants 32 Ciencias Médicas
description	The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage range: 79–99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.
publishDate	2024
dc.date.none.fl_str_mv	2024 2024-06-05 2024 2024-02-08 2024 2024-02-08
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	http://hdl.handle.net/20.500.12466/4335
url	http://hdl.handle.net/20.500.12466/4335
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir instname:Universidad Católica de Valencia San Vicente Mártir
instname_str	Universidad Católica de Valencia San Vicente Mártir
reponame_str	RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
collection	RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869422841293701120
score	15,300724

Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

Similares en LA Referencia